← Back to Search

Procedure

PEFA Ablation Technique for Ventricular Tachycardia (PEFA-VT Trial)

N/A

Recruiting

Led By Damian Redfearn

Research Sponsored by Dr. Damian Redfearn

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Greater than 18 years of age

Eligible for catheter ablation as standard of care

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

PEFA-VT Trial Summary

This trial looked at how well an ICD worked in people with heart disease.

Who is the study for?

This trial is for adults over 18 with ischemic heart disease and a history of myocardial infarction, who have an ICD implanted and are eligible for catheter ablation. It's not suitable for those unable to consent, with severe heart failure symptoms or mechanical heart valves, blood clot in the heart, contraindication to heparin, life expectancy under one year, recent acute coronary syndrome or prior VT ablation.Check my eligibility

What is being tested?

The study tests the PEFA VT ablation technique on patients with ischemic ventricular tachycardia. This Canadian multicentre prospective cohort study involves 40 participants who have received therapy from an implantable cardioverter defibrillator due to their condition.See study design

What are the potential side effects?

While specific side effects are not listed here, typical risks associated with catheter ablation may include bleeding or infection at the site of insertion, damage to blood vessels or heart tissue, adverse reactions to anesthesia or medications used during the procedure.

PEFA-VT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 18 years.

Select...

I am a candidate for a procedure to correct heart rhythm problems.

Select...

I have had a heart attack or have heart disease confirmed by tests.

PEFA-VT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

All-cause mortality

Appropriate ICD shock

Incessant VT

+2 more

Secondary outcome measures

Appropriate anti-tachycardia pacing (ATP) from ICD

Escalation and De-escalation of antiarrhythmic medication

Inducible for ventricular arrhythmia

+1 more

PEFA-VT Trial Design

1Treatment groups

Experimental Treatment

Group I: PEFA targeted substrate ablationExperimental Treatment1 Intervention

Use of PEFA strategy to identify and target VT isthmuses.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Dr. Damian RedfearnLead Sponsor

Damian RedfearnPrincipal InvestigatorKingston Health Sciences Centre

Damian Redfearn, MDPrincipal InvestigatorQueen's University

Media Library

PEFA VT ablation technique (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT03870854 — N/A

Ventricular Tachycardia Research Study Groups: PEFA targeted substrate ablation

Ventricular Tachycardia Clinical Trial 2023: PEFA VT ablation technique Highlights & Side Effects. Trial Name: NCT03870854 — N/A

PEFA VT ablation technique (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03870854 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the primary aim of this investigation?

"The aim of this 3 year clinical trial is to reduce the amount of sustained ventricular tachycardia below a level that cannot be detected by an implantable cardioverter defibrillator (ICD). Secondary objectives include tracking changes in antiarrhythmic drug dosages due to efficacy or side effects, monitoring the total number of arrhythmias events over time, and measuring appropriate ATP from ICDs."

Answered by AI

How many individuals are eligible for inclusion in this research project?

"Affirmative. According to the clinicaltrials.gov database, this experiment is currently open for recruitment and was initially posted on August 13th 2019 . 40 subjects are needed from 3 separate medical sites with the most recent update occurring on August 2nd 2022."

Answered by AI

Is recruitment for this medical experiment still open?

"Correct. Data hosted on clinicaltrials.gov confirms that, as of August 2nd 2022, this medical study is actively seeking candidates for enrollment; the trial was initially posted back in August 2019 and requires 40 participants from 3 distinct sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Paced Electrogram Feature Analysis (PEFA) for Ablation Targeting in Ischaemic Ventricular Tachycardia

Dr. Damian Redfearn 2019. "Paced Electrogram Feature Analysis (PEFA) for Ablation Targeting in Ischaemic Ventricular Tachycardia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03870854.